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ABSTRACT
The ribosome represents a major target for antibac-
terial drugs. Being a complex molecular machine, it
offers many potential sites for functional interfer-
ence. The high-resolution structures of ribosome
in complex with various antibiotics provide a
unique data set for understanding the universal
features of drug-binding pockets on the ribosome.
In this work, we have analyzed the structural and
evolutionary properties of 65 antibiotic binding
sites (ABSs) in the ribosome. We compared these
sites to similar-size computed pockets extracted
from the small and large ribosomal subunits.
Based on this analysis, we defined properties of
the known drug-binding sites, which constitute the
signature of a ‘druggable’ site. The most noticeable
properties of the ABSs are prevalence of non-paired
bases, a strong bias in favor of unusual syn con-
formation of the RNA bases and an unusual sugar
pucker. We propose that despite the different geo-
metric and chemical properties of diverse antibiot-
ics, their binding sites tend to have common
attributes that possibly reflect the potency of the
pocket for binding small molecules. Finally, we
utilized the ensemble of properties to derive a
druggability index, which can be used in conjunction
with site functionality information to identify new
drug-binding sites on the ribosome.
INTRODUCTION
The ribosome is responsible for protein synthesis in all
living cells. The bacterial 70S ribosome is formed by the
association of the large (50S) subunit and the small (30S)
subunit. The small subunit interprets the genetic informa-
tion encoded in the messenger RNA (mRNA), and the
large subunit catalyzes polymerization of amino acids
into a polypeptide. The ribosome is an RNA-based
machine; the RNA accounts for about two-thirds of the
molecular weight of each subunit. The 23S rRNA,
 2900nt long, and the 5S rRNA, comprised of  120nt,
associate with some 30 proteins to form the large riboso-
mal subunit. The small subunit contains an  1500-nt-long
16S rRNA plus 20 proteins (1). The high-resolution crys-
tallographic and cryo-EM structures of the ribosome and
its subunits support the results of many years of genetic
and biochemical studies conﬁrming that the main function
of the ribosome is promoted by rRNA (2–4).
The ribosome has been an important target for antibiot-
ics, both natural and synthetic (5). Structural and genetic
studies show that most of the drugs inhibiting ribosome
functions interact directly with rRNA. Despite the ribo-
some’s enormous size and the diversity of natural and
synthetic inhibitors of translation, the majority of clinic-
ally eﬀective antibiotics bind to only a few functional sites
in the ribosome. For example, most antibiotics that act on
the large ribosomal subunit, including diverse antibiotic
classes such as phenicols, lincosamides, streptogramins,
macrolides, oxazolidinones and others, bind at or near
the peptidyl transferase center (PTC), which is located in
a cavity on the interface side of the large subunit. The
binding of these compounds interferes with the catalysis
of peptide bond formation and/or the progression of the
nascent peptide toward the exit tunnel. Similarly, several
families of aminoglycoside drugs, including important and
diverse antibiotics, such as neamine, ribostamycin,
neomycin B, gentamycin, tobramycin, paromomycin,
etc., interact with the decoding center in the bacterial
16S rRNA. Notably, some of the antibiotics (such as
edeine or pactamycin), which broadly aﬀect protein syn-
thesis in all kingdoms of life, are not clinically relevant due
to their limited selectivity (6). In addition, it is important
to mention that some antibiotics, e.g. tetracyclines, were
demonstrated to bind to both a primary (clinically
relevant) site as well as to secondary sites which may not
be clinically relevant (7).
High evolutionary conservation of many rRNA regions
on the ribosome suggests their functional importance (8).
Key ribosomal activities have been assigned to several
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many other sites in the ribosome remains an enigma.
Although it is clear that complex processes, such as trans-
location, signal transduction, interaction with multiple
cellular ligands and many other ribosome-associated
activities that are central to protein synthesis, must
involve speciﬁc sites on the ribosome. In theory, some of
these cryptic functional sites could be good candidates for
antibiotic action. Indeed, in recent years, the binding of
antibiotics to previously unrecognized sites on the
ribosome has been reported (9–14). Furthermore, genetic
and biochemical screening methods have been employed
to reveal ribosomal sites whose structure is essential for
protein synthesis (15–17). It remains unknown, however,
which of these sites could be targeted by antibiotics.
A number of high-resolution structures of ribosome–
antibiotic complexes have been obtained recently using
X-ray crystallography. These structures provide fertile
ground for attempts to identify common features of anti-
biotic binding sites (ABSs) and to deduce what
distinguishes a ‘true’ ABS from other ‘pockets’ in the
ribosome. Moreover, the observed variability in antibiotic
binding justiﬁes the search for new sites and improved
compounds. Pursuing the general goal of identifying new
antibiotic sites in the ribosome, here, we comprehensively
analyzed 65 experimentally conﬁrmed ABSs extracted
from high-resolution structures of ribosome–drug
complexes and identiﬁed common characteristics of the
drug-binding pockets.
MATERIALS AND METHODS
Pocket extraction and parameter calibration
Extracting known ABS. Structures of Thermus
thermophilus and Escheruchia coli 30S, as well as
Haloarcula marismortui and Deinococcus radiodurans 50S
ribosomal subunits in complex with various ligands (anti-
biotics) were obtained from the Protein Data Bank (PDB).
The complete list of 65 crystal structures of ribosome–
antibiotics complexes is presented in Table 1. A binding
site was deﬁned to include all atoms within a radius of 6A ˚
from any atom of the ligand. PDB ID 2HHH with
identiﬁer KSG 1524 was excluded from the table due to
the low number of nucleotides at its binding site.
Furthermore, the atoms of the binding sites were deﬁned
in the apo structures of the small ribosomal subunit of
T. thermophilus (PDB 1J5E) (18) and E. coli (PDB
2AVY) (19), and the large ribosomal subunit of H.
marismortui (PDB 1JJ2) (20) and D. radiodurans (PDB
2ZJR) (21). These structures were then used to calculate
the structural properties for centrality measures calcula-
tions and for extracting putative pockets in the ribosome,
as described below.
Extracting putative pockets in the ribosome. The program
‘solvent’ from the 3V package (http://geometry
.molmovdb.org/3v/) was applied to identify putative
pockets in the ribosome (22). Brieﬂy, the program gets
as an input a PDB ﬁle and the radius of a small and a
large probe sphere, and outputs the void in the ribosome
structures that can accommodate a small probe size but
not a large probe size. The void itself, which corresponds
to a possible binding pocket, is represented by the oxygen
atoms of water molecules that deﬁne the borders of the
void (i.e. the surface of the pocket). The program was
applied to the PDB IDs 1J5E, 2AVY, 1JJ2 and 2ZJR
ﬁles, excluding ions and including all ATOM coordinates
(rRNA and ribosomal proteins). Grid spacing was
set to 1A ˚ .
Small probe and large probe radii calibration. The calibra-
tion procedure was applied to deﬁne the parameters
generating computed pockets that best ﬁt the average di-
mension of the known binding pockets (Table 1). The
calibration procedure was performed individually for
each of the 11 selected known binding pockets that have
 30% atoms in common (Table 1, indices; 2, 3, 4, 11, 12,
13, 23, 25, 31, 34 and 35).
Previous studies have shown that the large ribosomal
subunit (PDB 1JJ2) contains no cavities big enough to
enclose a sphere having a radius greater than 9.5A ˚ .
Thus, in the ﬁrst round of calibration, the large probe
radius was ﬁxed to 9.5A ˚ , while the small probe radius
was gradually reduced (1A ˚ decline) in the 1.5–8.5A ˚
range. After each individual run of the ‘solvent’ algorithm
with a deﬁned set of parameters, the surface of the pockets
was delineated by the coordinates of computed oxygen
atoms of water molecules. The relativity between a
computed pocket and a known binding site was described
by the minimal distance between the computed oxygen
atoms and the center of mass of all atoms included in
the known binding sites. This procedure was repeated
for each known ABS, testing the full range of small
probe radii in order to deﬁne the optimal parameters for
which the shortest distance between known and computed
pockets was reached. Finally, a small probe radius of 1.5A ˚
was chosen as the optimal radius that gave the best results
for all known binding pockets tested (Supplementary
Table S1). The size of the small probe indicates accessibil-
ity of the computed pockets to solvent water molecules.
To decrease the number of computed binding pockets
and eliminate pockets that do not match the dimension of
known binding sites, a second round of calibration was
performed. In the second round, only the size of the large
probe radius was decreased, while the small probe radius
was ﬁxed to 1.5A ˚ . Finally, after gradually decreasing the
large probe, a radius of 5.5A ˚ was chosen, keeping the
distance from the computed pocket to the known
binding sites at a minimum (Supplementary Table S2).
Size of the computed pockets. To deﬁne the computed
pocket boundaries, we examined various radii cutoﬀs
around the computed oxygen atoms (Supplementary
Table S3). For each radius, we deﬁned the pocket size as
the number of nts it comprises, i.e. a nt was considered in
the computed pocket if it had at least one atom within a
deﬁned radius. A radius of 9A ˚ around the computed
oxygen atoms was chosen, as it resulted in approximately
the same average number of nts as in the known binding
sites (Supplementary Table S3). Finally, we retained only
pockets that comprise 12nt and diﬀer in at least 1nt,
Nucleic Acids Research, 2010,Vol.38, No. 18 5983Table 1. Crystallographic structures of T. thermophilus (T.t) and E.coli (E.c) small subunit, and H. marismortui (H.m) and D. radiodurans (D.r)
large subunit complexed to antibiotics
Index Subunit Antibiotics MW (Da) Organism PDB Identiﬁer Resolution Refs
1 30S Hygromycin B 527.52 T.t 1HNZ HYG 3.3A ˚ (53)
2 30S Pactamycin 558.62 T.t 1HNX PCY 3.4A ˚ (53)
3 30S Tetracycline 444.44 T.t 1HNW TAC 1001 3.4A ˚ (53)
4 30S Tetracycline 444.44 T.t 1HNW TAC 1002 3.4A ˚ (53)
5 30S Tetracycline 444.44 T.t 1I97 TAC 2001 4.5A ˚ (7)
6 30S Tetracycline 444.44 T.t 1I97 TAC 2003 4.5A ˚ (7)
7 30S Tetracycline 444.44 T.t 1I97 TAC 2004 4.5A ˚ (7)
8 30S Tetracycline 444.44 T.t 1I97 TAC 2005 4.5A ˚ (7)
9 30S Tetracycline 444.44 T.t 1I97 TAC 2006 4.5A ˚ (7)
10 30S Edeine 781.9 T.t 1I95 EDE 4.5A ˚ (7)
11 30S Spectinomycin 332.35 T.t 1FJG SCM 3A ˚ (54)
12 30S Streptomycin 581.57 T.t 1FJG SRY 3A ˚ (54)
13 30S Paromomycinaromomycin 615.63 T.t 1FJG PAR 3A ˚ (54)
14 30S Kasugamycin 379.36 T.t 2HHH KSG 1523 3.35A ˚ (57)
15 30S Hygromycin B 527.52 E.c 3DF1 HYG 3.5A ˚ (58)
16 30S Spectinomycin 332.35 E.c 2QOU SCM 3.93A ˚ (59)
17 30S Kasugamycin 379.36 E.c 1VS5 KSG 3.5A ˚ (60)
18 30S Gentamicin 449.54 E.c 2QB9 LLL 2356 3.54A ˚ (10)
19 30S Gentamicin 449.54 E.c 2QB9 LLL 2357 3.54A ˚ (10)
20 30S Gentamicin 449.54 E.c 2QB9 LLL 2357 3.54A ˚ (10)
21 30S Neomycin 614.64 E.c 2QAL NMY 3.21A ˚ (10)
22 50S Erythromycin 733.93 H.m 1YI2 ERY 2.65A ˚ (56)
23 50S Azithromycin 748.99 H.m 1YHQ ZIT 2.4A ˚ (56)
24 50S Telithromycin 812.01 H.m 1YIJ TEL 3.4A ˚ (56)
25 50S Quinupristin 1022.22 H.m 1YJW SYB 2.9A ˚ (56)
26 50S Virginiamycin S 823.89 H.m 1YIT VRS 2.8A ˚ (56)
27 50S Virginiamycin M 525.59 H.m 1YIT VIR 2.8A ˚ (56)
28 50S Clindamycin 424.98 H.m 1YJN CLY 3A ˚ (56)
29 50S Carbomycin 841.98 H.m 1K8A CAI 3A ˚ (35)
30 50S Spiramycin 843.05 H.m 1KD1 SPR 3A ˚ (35)
31 50S Tylosin 916.1 H.m 1K9M TYK 3A ˚ (35)
32 50S Sparsomycin 361.44 H.m 1M90 SPS 2.8A ˚ (55)
33 50S Chloramphenicol 323.13 H.m 1NJI CLM 2.55A ˚ (3)
34 50S Anisomycin 265.31 H.m 1K73 ANM 3.01A ˚ (3)
35 50S Blasticidin S 422.44 H.m 1KC8 BLS 9001 3.01A ˚ (3)
36 50S Blasticidin S 422.44 H.m 1KC8 BLS 9002 3.01A ˚ (3)
37 50S Homoharringtonine 545.62 H.m 3G6E HMT 2.7A ˚ (61)
38 50S Bruceantin 548.58 H.m 3G71 WIN 3.85A ˚ (61)
39 50S Tiamulin 493.74 H.m 3G4S MUL 3.2A ˚ (61)
40 50S Oxazolidinone 513.52 H.m 3CXC SLD 3A ˚ (62)
41 50S Girodazole 190.63 H.m 2OTL GIR 2.7A ˚ (12)
42 50S 13-deoxytedanolide 594.73 H.m 2OTJ 13T 2.9A ˚ (12)
43 50S Erythromycin 733.93 D.r 1JZY ERY 3.5A ˚ (63)
44 50S Clindamycin 424.98 D.r 1JZX CLY 3.1A ˚ (63)
45 50S Clarithromycin 747.95 D.r 1J5A CTY 3.5A ˚ (63)
46 50S Roxithromycin 837.05 D.r 1JZZ ROX 3.8A ˚ (63)
47 50S Chloramphenicol 323.13 D.r 1K01 CLM 3.5A ˚ (63)
48 50S Azithromycin 748.99 D.r 1NWY ZIT 1 3.3A ˚ (64)
49 50S Azithromycin 748.99 D.r 1NWY ZIT 2 3.3A ˚ (64)
50 50S Cethromycin 765.93 D.r 1NWX 773 3.5A ˚ (64)
51 50S Telithromycin 812.01 D.r 1P9X TEL 3.4A ˚ (65)
52 50S Quinupristin 1022.22 D.r 1SM1 SYB 3.42A ˚ (66)
53 50S Dalfopristin 690.85 D.r 1SM1 DOL 3.42A ˚ (66)
54 50S Sparsomycin 361.44 D.r 1NJN SPS 3.7A ˚ (67)
55 50S Troleandomycin 813.97 D.r 1OND TAO 3.4A ˚ (68)
56 50S Tiamulin 493.74 D.r 1XBP MUL 3.5A ˚ (69)
57 50S Thiostrepton 1664.89 D.r 3CF5 TXX 3.3A ˚ (21)
58 50S Oxazolidinone 337.35 D.r 3DLL ZLD 3.5A ˚ (70)
59 50S SB-571519 498.57 D.r 2OGM G19 3.5A ˚ (45)
60 50S SB-280080 477.70 D.r 2OGN G80 3.56A ˚ (45)
61 50S SB-275833 517.76 D.r 2OGO G34 3.66A ˚ (45)
62 50S Rapamycin 914.17 D.r 1Z58 RAP 3.8A ˚ (13)
63 50S Josamycin 828.00 D.r 2O44 JOS 3.3A ˚ (71)
64 50S RU-69874 972.22 D.r 2O45 RU6 3.6A ˚ (71)
65 50S Erythromycylamine 734.96 D.r 2O43 ERN 3.6A ˚ (71)
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pockets that we refer to as the background. The number
of pockets calculated for all structures used in this study is
listed in Supplementary Table S4.
Speciﬁcity and sensitivity of binding site identiﬁcation
Speciﬁcity and sensitivity were calculated based on the
degree of overlap between the computed pockets and the
known binding sites (Supplementary Table S5).
‘Overlapping speciﬁcity’ equals the fraction of common
nts in the putative and the known pockets divided by
the number of nts in the known binding site.
‘Overlapping sensitivity’ equals the fraction of common
nts divided by the number of nts included in the
putative (computed) pocket.
Physicochemical properties
The nitrogen and oxygen atoms in the base were classiﬁed
as donors or acceptors. Backbone oxygen atoms were
labeled as sugar or phosphate.
Structural properties
For the RNA structural properties classiﬁcation, including
base-pairing (23,24) and base-base stacking interactions
(25), the MC-Annotate (version 1.6.2) program (26) was
used. Base-pairing was deﬁned according to three edges of
the corresponding RNA bases available for H-bonding
interactions, labeled the Watson–Crick (W) edge, the
Hoogsteen edge (H) and the Sugar edge (S). For more
details see refs. 25 and 28. Base–base stacking interactions
were categorized as stacking interactions between adjacent
and non-adjacent nts. For more details see ref. 27.
The features were extracted as described in ref. 28 using
an in-house Perl script converting the MC-Annotate
output ﬁles into binary format, i.e. each nt was given a
score of ‘1’ when a speciﬁc property was present and a
score of ‘0’ when it was absent. To calculate the relative
abundance of a speciﬁc property, the fraction of nts in the
pocket having this property was calculated. In order to
generate the signature of the binding sites (Table 1),
only properties covering at least 1% of all rRNA nts
were included.
Functional sites
Interface residues of the 16S rRNA and 23S rRNA with
ribosomal proteins mRNA and tRNA were calculated
using the Intervor web server (http://cgal.inria
.fr/abs/Intervor) (29) with default parameters. The inter-
face with ribosomal proteins was calculated on the PDB
IDs 1JJ2 and 1J5E. The interface with the tRNA and
mRNA was calculated on the PDB IDs 2J00 and 2J01
(30). The A-minor motif annotation (PDB ID’s 1VQO,
2J00) was downloaded from http://www.biomath.nyu
.edu/motifs/rrna.html.
Centrality measures
We modeled the 16S rRNA (PDB IDs 1J5E, 2AVY) and
the 23S rRNA (PDB IDs 1JJ2, 2ZJR) as a structure-based
network of interacting nts (31). Brieﬂy, each nt was
considered as a node in the network, and chemical inter-
actions between nts deﬁned the edges. The degree of a
node i is deﬁned as the number of edges connected to i.
The betweenness of a node i is deﬁned by the number of
shortest paths that cross node i. The closeness of a node i
is deﬁned as the inverse average length of the shortest
paths to all other nodes in the graph (32). The closeness
of node i is given in Equation (1)





where N is the total number of nodes in the network, and
dij is the shortest path length to node i. For each known
binding site and computed pocket, we calculated the
average closeness, betweenness and degree.
Evolutionary conservation
Aligned sequences and a guide tree for both the 16S/18S
and the 23S/28S were downloaded from the ARB-SILVA
database (release 96) (http://www.arb-silva.de). The
16S/18S alignment comprises high-quality sequences,
with a minimum length of 1200 bases for bacteria and
eukarya and 900 bases for archaea. The 23S/28S align-
ment comprises high-quality rRNA sequences with a
minimum length of 1900 bases. Positional variability in
bacteria was calculated with the ARB package using par-
simony function (37). The score of the evolutionary rate
was multiplied by  1 to create values of evolutionary
conservation.
Statistical analysis
The relative abundance of each property in a known site
was evaluated relative to a background of putative
pockets. Since we could not assume normality, an individ-
ual score (ui) of each property was standardized as given in
Equation (2):
ui ¼
xi   medianðxiÞ
MAD
ð2Þ
MAD denotes the median absolute deviation, given by
Equation (3):
MAD ¼ median xi   medianðxiÞ
          
ð3Þ
The statistical signiﬁcance of the structural properties and
16 types of base pairing presentation in ABSs was
evaluated based on the hyper geometric distribution
using the Fisher’s exact test.
RESULTS AND DISCUSSION
Identifying putative ligand-binding pockets in the ribosome
To study the distinguishing characteristics of ABSs in the
ribosome, we sought to compare the properties of known
ABSs (Table 1) to a collection of computed structural
pockets having similar dimensions. We deﬁned a ‘known
ABS’ as all rRNA atoms within 6A ˚ from any atom of the
ligand (antibiotic) observed in the crystal structure of an
Nucleic Acids Research, 2010,Vol.38, No. 18 5985antibiotic-ribosome complex. We then selected the coord-
inates of the corresponding rRNA atoms in the
apo-structure, which represented the unbound
drug-binding pocket (see ‘Materials and Methods’
section). To generate the collection of structural pockets
in both ribosomal subunits, we ﬁrst calibrated the param-
eters of the pocket-extraction protocol to correctly
identify the known ABSs, and then used these parameters
to identify all other similar pockets. Since the majority of
antibiotics that bind the ribosome interact mostly with the
ribosomal RNA (rRNA) (33), we chose to concentrate on
pockets that consist exclusively of rRNA. The location
and composition of the pockets were computed using
the ‘small and the large probe spheres’ approach, previ-
ously applied for identifying ligand-binding sites in
proteins (34). Here, we deﬁned a pocket as a volume in
the ribosome into which a small probe can enter but a
large probe cannot. For automatic extraction of the
pockets, we adopted the program ‘solvent’ from the 3V
package (http://geometry.molmovdb.org/3v/) on a 1A ˚
grid space (22).
Testing the pocket extraction procedure
A plausible way of evaluating the pocket extraction pro-
cedure would be to examine the degree of inclusion of the
known ABSs in the collection of all computed pockets
(Supplementary Tables S1–S4). To achieve a maximum
overlap between the extracted pockets and the known
binding sites, we applied a calibration procedure that
tested diﬀerent small and large probe radii (see
‘Materials and Methods’ section). After selecting the
optimal probe radii (Supplementary Tables S1–S2), we
set the size of the computed pocket to be equal to the
average number of nts in the known ABS
(Supplementary Table S3). Finally, we deﬁned the
optimal parameters for the pockets (1.5A ˚ for the small
probe radius, 5.5A ˚ for the large probe radius, and a
pocket size of 12nts). These parameters yielded a
minimal number of computed pockets that provides
a maximal overlap with the known ABSs. Overall, the
overlapping values between the known and computed
pockets were in the range between 50% and 100 %
(Supplementary Table S5). The high accuracy of pocket
extraction is exempliﬁed in Figure 1, which illustrates the
overlap between a computed pocket and the known ABS
of tetracycline in the 16S rRNA (Figure 1A), and the
erythromycin binding site in the 23S rRNA (Figure 1B).
The high overlap between computed and known sites
indicates that the computational procedure used in this
study is suitable for identifying putative pockets with
similar dimensions to the known ABSs.
Having applied the procedure to the apo-structures of
the T. thermophilus small ribosomal subunit (PDB ID
1J5E) and the H. marismortui large subunit (PDB ID
1JJ2), we extracted a total of 17610 overlapping pockets
that diﬀer in at least 1 nt (Supplementary Table S4). The
large number of pockets is not surprising given the
enormous size of the ribosome, and is consistent with
the notion that the RNA component of the ribosome
presents a large network of interconnected channels that
are readily accessible to small ligands (22). Furthermore,
the discrepancy between the large number of putative
pockets and the number of experimentally deﬁned ABSs
implies that the dimension parameter alone is not a suﬃ-
cient criterion to explain the speciﬁc binding of antibiotics
to the rRNA.
Properties of the drug-binding pockets
Despite the high number of potential binding pockets for
small molecules in the ribosome, known ribosomal inhibi-
tors act on a limited number of sites. In order to identify
the properties distinguishing a real ABS from other
Figure 1. Overlapping between the computed pockets and the observed binding sites. (A) Tetracycline bound to its primary binding site (53). The
rRNA molecular surface (PDB ID 1HNW) is presented in grey; tetracycline is presented as blue sticks. The computed pocket showing the highest
overlapping sensitivity (67%) and speciﬁcity (89%) is colored yellow. The pocket was calculated on the crystal structure of T. thermophilus (PDB ID
1J5E) and was superimposed to the bound structure (PDB ID 1HNW). (B) Erythromycin binding pocket (56). The rRNA molecular surface (PDB
ID 1YI2) is presented in gray; erythromycin is presented as blue sticks. The computed pocket showing the highest overlapping sensitivity (75%) and
speciﬁcity (82%) is colored yellow. The pocket was calculated on the crystal structure of H. marismortui, (PDB ID 1JJ2), and was superimposed to
the bound structure (PDB ID 1YI2).
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a set of physical, chemical and structural features (listed in
Supplementary Table S6), as well as the extent of evolu-
tionary conservation for both the experimentally validated
ABSs and for all computed pockets. Clearly, apart from
evolutionary conservation, a very important feature that is
expected from clinically aﬀective antibiotic binding sites is
their speciﬁcity to the drug (i.e. the binding site in patho-
genic bacteria should diﬀer from the corresponding site in
the host ribosome). However, since bacterial speciﬁcity
usually boils down to a single nucleotide [as in the
macrolide binding pockets (35)] which could not be
identiﬁed in our statistic-based method and is not
expected from all ABSs that we have included in our
analysis (i.e. the archaeal ABSs), we did not incorporate
speciﬁcity among the computed parameters. The selected
features (Supplementary Table S6) were further compared
between known binding sites and all computed pockets.
To further test whether the properties that over repre-
sented in ABSs in of both the T. thermophilus, and
H. marismortui are unique to druggable sites, we
examined their abundance in both ribosomal
protein-binding interfaces and in sites that consist of
ribosome–ligands interactions. Speciﬁcally, we included
nucleotides that interact with the mRNA and the tRNA,
i.e. the A, P and E sites (see ‘Materials and Methods’
section). The properties of the 65 known binding sites,
which exhibit statistically signiﬁcant bias compared to
all computed pockets, are presented in Figure 2 and are
discussed in more detail in the subsequent paragraphs.
RNA nucleotides and bases. When analyzing the structural
composition of the known ABSs in comparison to the
computed pockets, we noticed an increased representation
of atoms belonging to the nitrogen bases rather than
atoms of the sugar-phosphate backbone. This phenom-
enon was prominent speciﬁcally in binding sites of the
large ribosomal subunit (Figure 2A, indices 22–63). The
overabundance of atoms of the nitrogen bases in the ABSs
may reﬂect the known sequence speciﬁc interactions of
many antibiotics with the ribosome that form the basis
of selectivity of clinically important medicines.
Nevertheless, we did not identify a statistically signiﬁcant
preference for a speciﬁc type of nitrogen base or an
explicit donor/acceptor group in the known ABSs
(Figure 2A). Upon examining the occurrence of the 16
possible base pairs (26) in ABSs (see ‘Materials and
Methods’ section), we noticed a signiﬁcant overrepre-
sentation of the non canonical UC base pair and an
underrepresentation of the canonical UA pair in the 23S
rRNA binding sites. Furthermore, the GC was
underrepresented in ABSs in both 16S and 23S rRNA.
Notably, such bias was speciﬁc to ABSs and was not
observed in the ribosomal protein-binding interface,
while the GC and UA underrepresentations were found
in the natural ligand-binding sites in the large subunit
(Supplementary Table S7).
Structural properties
The most apparent bias in the characteristics of the known
ABSs was the overrepresentation of non-paired bases
(Figure 2C). This phenomenon was more prominent in
the large ribosomal subunit (Supplementary Table S7
and S8). Non-paired bases obviously oﬀer a greater
variation in the chemical groups available for
structure-speciﬁc interaction with the drug (or natural
ligand) compared to the nitrogen bases engaged in the
inter-nucleotide interactions. Therefore, rRNA pockets
Figure 2. The ‘RNA signature’ of antibiotic binding sites. Binding site indices are presented in Table 1. The color scheme refers to the standardized
score against a background of 17610 computed pockets [‘Materials and Methods’ section, Equation (3)]. Scores were scaled to range from  1t o1 .
Signiﬁcant biases relative to the background median are colored red and blue, respectively. (A) Physicochemical properties, (B) Nucleotides types,
(C) Structural classiﬁcation according to the program MC-annotate (26), (D) Centrality measures, (E) Evolutionary conservation. For convenience,
the Watson–Crick edge was abbreviated to W, the sugar edge to S and the Hoogsteen edge to H.
Nucleic Acids Research, 2010,Vol.38, No. 18 5987with the higher representation of non-paired bases could
be evolutionary selected as preferred ABSs. We further
analyzed various types of interactions between the nts in
the pockets. Interactions were annotated according to
three edges of H-bonding interactions [Watson–Crick
(W)/Hoogsteen (H)/Sugar (S)] (24,27). Further, base–
base interactions were categorized in terms of stacking
interactions between adjacent and non-adjacent nts (26).
We observed a bias to the non-canonical W-H pairing in
the known ABSs. Additionally, we noted an overrepre-
sentation of non-adjacent base–base stacking interactions
in the large ribosomal subunit (Figure 2C).
The A-minor motif, which involves inserting the edges
of adenine bases into the minor groove of RNA helices,
was previously found to be the most abundant structural
motif in the large ribosomal subunit (36–39). Consistent
with previous observations showing the importance of the
A-minor motif in functional sites (51), we found that a
considerable number (Supplementary Table S9) of ABSs,
speciﬁcally in the 16S rRNA, comprise diverse elements of
the A-minor motif. Overall, the results of structural
analysis of RNA bases in the ABSs are consistent with
the notion that antibiotic binding, both in the large and
small subunits, involves RNA nts belonging to
single-stranded RNA regions or distortions in the RNA
helices such as in bulges, loops, etc. (40).
Interestingly, we also observed a preference for syn over
anti conformation of the RNA bases in the majority of
known ABSs (Supplementary Tables S7 and S8). Syn and
anti conformations are deﬁned by the glycosidic torsion
angle  . It was previously shown that the syn conform-
ation has higher energies than the anti conformation in
pyrimidine nucleosides (41). The sugar conformation is
known to have a great eﬀect on the distribution of glyco-
sidic torsion angles. Speciﬁcally, the C2 endo sugar pucker
provides less steric hindrance than the C3 endo, allowing a
wider range of   values and less energy cost for a syn
conformation (19,30). Consistent with the latter, we
found that the ribose sugar pucker in C3 endo conform-
ation was underrepresented in the vast majority of ABSs.
The relative overabundance of the unusual sugar pucker
conformation (both C2 endo and C4 exo) and syn con-
formation of RNA bases in ligand-binding sites could be
associated with the higher ﬂexibility of rRNA in these sites
(42,43). The ﬂexibility of the glycosidic bonds of the bases
in the antibiotic binding sites of the large ribosomal
subunit (speciﬁcally at the PTC and the tunnel region)
was recently suggested to explain antibiotic selectivity
and action (44). Possibly during evolution, antibiotics
were selected to target ﬂexible RNA pockets that are
capable of the induced ﬁt-binding mode (45). Consistent
with the result in the 23S rRNA, a preference for
non-paired bases and the syn conformation was also
observed in the 16S rRNA (Figure 2).
Interestingly, we observed that stacking interactions
(both adjacent and non-adjacent) are underrepresented
in the ribosome–ligand-binding interface, but the
non-adjacent interactions are overrepresented in both
the ABSs and protein binding of the 23S rRNA
(Supplementary Table S7). Remarkably, in the
protein-binding interface, we could not identify bias to
the non-paired bases, Watson–Hoogsteen pairing, syn
conformation, or irregular sugar pucker. Comparison of
structural properties of known antibiotic sites between the
T. thermophilus and Escherichia coli ribosomes (34)
showed that the preference for non-paired nts,
non-adjacent base-base stacking interactions, and high oc-
currence of syn conformation appear to be conserved
between ribosomes of diﬀerent bacterial species
(Figure S1). The conservation of unique properties in
the binding pockets of these species emphasizes the im-
portance of the unique structural properties to the
function of these sites.
Centrality and evolutionary conservation. Recent studies
have employed the network (graph) approach to analyze
unique properties of macromolecule structures (31,46–48).
In such structure-based networks, the amino-acids/bases
are represented as nodes, and inter-residue interactions as
edges. In a previous study, we showed that the centrality
parameters (i.e. closeness, betweenness and degree) were
highly correlated with functionality of the nt in the
ribosome (31). As demonstrated in Figure 2D, we found
that the nts in most known ABSs are characterized with
high centrality values, and a speciﬁcally high closeness.
When we further calculated the evolutionary conservation
for the three domains of life (bacteria, archaea and
eukarya) using the ARB-SILVA database (49), a high
degree of conservation was observed in most ABSs. This
observation is in accord with previously noted evolution-
ary conservation of rRNA in the functional centers of the
ribosome (Figure 2E) (50).
Summarizing our ﬁndings discussed in the previous
paragraphs, we note that the known sites of antibiotic
binding in the ribosome are preferentially endowed with
speciﬁc structural properties. Characteristics such as the
prevalence of the A-minor motif (42,51) and high central-
ity values (31) have been previously shown to be
associated with ribosome functional sites. Therefore, we
tested whether the other structural properties distinguish-
ing the ABSs could be attributable to the functional sites
in general. Upon selecting a subset of top 25% highly
conserved nts, we found that they exhibit a property
bias similar to that found for the antibiotic sites, such as
overabundance of non-paired bases, unusual sugar pucker
and prevalence of syn conformation (Figure 3). These
results are also consistent with the above analysis of
mRNA and the A, P and E sites, in which we observed
bias in favor of non-paired bases and the syn conform-
ation, while an underrepresentation was observed in the
C3 endo conformation and canonical Watson–Crick base
pairing (GC) (Supplementary Table S7). Likely, the bias
we observed in ABSs reﬂects the unique structural
properties of functional sites on the ribosome that contrib-
ute to the high aﬃnity binding of their natural ligands.
New antibiotic sites for future drug design
Knowledge of the properties of known ABSs can illumin-
ate which other pockets in rRNA could serve as binding
sites for new antibiotics. However, clearly further research
on site functionality and speciﬁcity is required. In order to
5988 Nucleic Acids Research, 2010,Vol.38, No. 18estimate whether a computed pocket can be a potential
drug-binding site, we assigned a ‘druggability index’ (DI)
score [Equation (4)] to each computed pocket. DI weights
the properties that were found signiﬁcantly biased in the






where x is a property presented in Supplementary Table
S7, Px is the P-value of property x, and Fx is the fraction
of nts in the computed pocket with property x. It is im-
portant to note that the DI was derived from the prefer-
ences for speciﬁc structural properties we observed mainly
in the large subunit (Figure 2). As a result, we applied the
DI to identify new structural pockets exclusively in the
large ribosomal subunit. Figure 4 plots the DI values of
computed pockets in the large ribosomal subunit with DI
>0 (comprising 63% of all computed pockets) versus their
calculated average evolutionary conservation, usually
employed to identify functional sites.
As shown, while many computed sites in the 23S rRNA
possess a very high conservation (demonstrated by the
high density of dots in the right-hand side of Figure 4),
we found that the computed pockets that overlap with the
known ABSs are both highly conserved and possess a high
DI score, which mainly reﬂects their unique structural
properties (Figure 4, red dots). Interestingly, among the
known sites of antibiotic action, the computed site that
overlapped the macrolides binding pocket in the nascent
peptide exit tunnel had the highest DI value. The top four
ranked computed pockets (with the highest DI scores) are
presented in Figure 5. Three of them overlap experimen-
tally validated ABSs. Pockets 1 and 2 (Figure 5A and B)
overlap the binding sites of the macrolides and ketolides
antibiotics. The third top-ranking pocket (Figure 5C) is
located near the ribosomal E site and overlaps the binding
site of girodazole (12). The site ranked in fourth place
(Figure 5D) is located about 12A ˚ from the nascent
peptide tunnel close to the loop of ribosomal protein
L22. This computed site comprises a methylated residue
m
6A1618 (52) and is not targeted by any antibiotic cur-
rently in use. The overall distribution of the DI score over
the 23S rRNA molecular surface is presented in Figure 6.
As demonstrated, very high DI values were obtained in the
vicinity of the PTC and the E-site region. A zoom to the
E-site region showing a view into the exit tunnel is also
presented. As shown, the red (high DI) patch decorating
the tunnel walls is the region of macrolides-binding sites.
Notably, other regions of the large ribosomal subunit
demonstrate patches of high DI values, suggesting other
potential binding sites.
To test the validity of the DI score in clinically relevant
sites, we examined the DI scores of the tetracycline
computed pockets in the small subunit that comprise
both the clinically relevant primary site and additional
sites that may include non speciﬁc interactions with tetra-
cycline (53). Interestingly, of all sites the highest DI was
calculated for the primary binding site (1HNW, TAC1001,
DI=0.72; 1I97, TAC2001, DI=0.65); this score was
higher (Supplementary Table S10) than the secondary
site (1HNW TAC1002, DI=0.59) and the other
observed sites (1I97) (7). To further evaluate the potential
of DI to detect ABSs, we concentrated on sites possessing
a DI value that fell in the range of the DI of known ABSs
(0.44<DI<0.98). These sites accounted for 21% (i.e. 2487
pockets including the 606 known ABSs). Overall, we
Figure 4. The ‘druggability index’ (DI) versus evolutionary conserva-
tion. DI and evolutionary conservation values were rescaled from 0 to
1. All pockets with DI >0 (7482 pockets) calculated from the
H. marismortui large ribosomal subunit (PDB ID 1JJ2) are shown;
pockets overlapping known ABSs are colored red. Pockets including
a deleterious mutation are colored blue. Pockets that include a deleteri-
ous mutation and are located outside the PTC region are colored cyan.
Figure 3. Overrepresented and underrepresented properties in highly
conserved sites (top 25%). The 16S rRNA is presented in grey bars.
The 23S rRNA is presented in black bars. Bar height represents the
statistical signiﬁcance shown by the –log10 of the P-value. The red line
marks the level of statistical signiﬁcance (P=0.05).
Nucleic Acids Research, 2010,Vol.38, No. 18 5989Figure 5. Binding pockets on the ribosome with the highest ‘druggability index’ score. The rRNA molecular surface is shown in gray. The computed
pocket surface is shown in yellow. (A) The computed pocket with the highest DI score (DI=1.00). Erythromycin is presented as blue sticks (PDB ID
1YI2). (B) The computed pocket ranked in second place (DI=0.98). Telithromycin is presented as blue sticks (PDB ID 1YIJ). (C) The computed
pocket ranked in third place (DI=0.94). Girodazole is presented as blue sticks (PDB ID 2OTL). (D) The computed pocket ranked in fourth place
(DI=0.93).
180° 01
Figure 6. Druggability Index (DI) projected on the 23S rRNA molecular surface (PDB ID 1JJ2). A view into the exit tunnel is shown in the box.
Low and high DIs are colored blue and red, respectively. Color bar is shown.
5990 Nucleic Acids Research, 2010,Vol.38, No. 18indentiﬁed 1181 overlapping pockets on the 23S rRNA as
potential new druggable sites. Interestingly, several of
them overlap our previously detected deleterious point
mutations (16,17) (Figure 4, cyan and blue dots). As
shown in Figure 4, the conservation and DI of these
pockets resemble the values of known ABSs. Two 23S
rRNA sites outside PTC, the sarcin–ricin loop (centered
around nt 2664) and the internal loop in the A-site ﬁnger
(around nt 864) are characterized by clusters of deleterious
mutations that make them attractive candidates for drug
development. Of these two sites, the sarcin–ricin loop
pocket has a higher DI (DI=0.68) than the A-site
ﬁnger pocket (DI=0.49). Yet, the DI values of both
sites are high enough to place both of them in the list of
potentially druggable ribosomal sites.
Figure 7 further demonstrates the potential to combine
the DI with the existence of structural motifs preferentially
found in known binding pockets, such as the A-minor
motif. An example of such a putative site was found in
the A-site ﬁnger. The pocket was computed from the
H. marismortui structure (PDB 1JJ2) and has a DI value
of 0.49. This pocket consists of 12nt, six which
form non-adjacent base–base stacking interactions.
Additionally, the pocket has a UC mismatch base pair
(Figure 6; positions 913, 914), and an unpaired adenine
in position 910, which participates in an A-minor motif
interaction. The nts that were identiﬁed as A-minor motif
elements refer to positions 862 and 863, which form inter-
actions with adenines in the 5S rRNA. As discussed
above, these properties were commonly found in function-
al sites as well as in known ABSs. The functional role of
this highly conserved region is also denoted by the
presence of a strong deleterious mutation (position 864)
(17). Although the function of this region is unclear due to
its high DI value and overall functional characteristics, we
suggest that this pocket could be a good candidate for a
novel drug.
CONCLUSIONS
In an attempt to better understand the atomic and struc-
tural features that could elucidate the druggability of
ABSs on the ribosome, we studied the properties of 65
antibiotic binding pockets extracted from the available
high-resolution structures of ribosome-antibiotic
complexes (3,4,7,12,35,53–56). In addition, we applied
an automatic method to compute structural pockets
from the T. thermophilus and H. marismortui small and
large ribosomal subunits. Overall, we extracted  17000
overlapping computed pockets on the ribosome, all in
the same range of dimensions as the known binding
sites. The enormous number of computed binding sites
clearly shows that the ribosome, which is comprised of a
large network of interconnected channels, is much more
accessible to small ligands than traditional protein drug
targets. However, to date, only a small number of possible
binding pockets in the ribosome has been veriﬁed to bind
antibiotics.
Figure 7. Example of a computed pocket in H. marismortui with ‘druggable’ properties. The 12nt of the computed pockets are labeled (E. coli
numbering) and presented in balls and sticks. Six nucleotides in the pocket form non-adjacent stacking interactions. Positions 913 and 914 refer to
UC base pairs. The nucleotides corresponding to the strong deleterious mutation in position 864 is colored red. The pocket includes nts that involve
A-minor motifs (positions 862, 863 and 910).
Nucleic Acids Research, 2010,Vol.38, No. 18 5991A comprehensive analysis of the physicochemical and
structural (local and global) features of RNA in the
known antibiotic binding pockets revealed that while the
sites diﬀer in their dimension and atomic details, they
share several unique properties, namely an ‘RNA signa-
ture’. The most noticeable structural properties found in
the majority of known binding sites were the prevalence of
non-paired bases, preference for the unusual syn base con-
formation and unusual ribose sugar pucker. We postulate
that the unique base conformation and sugar pucker may
reﬂect higher ﬂexibility of the rRNA bases in the ABSs as
in natural ligands. We believe that the properties we
identiﬁed, speciﬁcally the suggested DI, will facilitate the
identiﬁcation of new functional sites suitable for drug
design. Clearly, other considerations such as bacterial spe-
ciﬁcity of the site and experimental validation of site func-
tionality will be required. Furthermore, we believe that a
similar approach could be implemented for characterizing
and identifying other ligand-binding sites in non-
ribosomal RNA targets (such as non-coding RNAs) for
which selective ligands are extremely scarce or do not
exist.
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